Literature DB >> 2225315

Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro.

A W Himmelmann1, S Danhauser-Riedl, G Steinhauser, R Busch, E J Modest, A Noseda, J Rastetter, W R Vogler, W E Berdel.   

Abstract

The synthetic ether lipids ET-18-OCH3 and BM41.440 and a derivative, hexadecylphosphocholine, were tested for inhibition of [3H]-thymidine uptake into a Chinese hamster ovarian cell line (AUXBl) and its multidrug-resistant subline selected for colchicine resistance (CHRC5). The activity of all three compounds against the multidrug-resistant subline was equal to or higher than that against the parent line. The same result was found for their activity against a human leukemic lymphoblastic cell line (CEM/O) and its methotrexate-resistant subline (CEM/MTX). In contrast, two multidrug-resistant cell lines selected for resistance to Adriamycin, the mouse leukemia cell line P388/ADR and the murine sarcoma cell line S180/ADR, expressed modest cross-resistance to the lipids as measured by thymidine uptake. Experiments performed using the trypan-blue dye-exclusion assay yielded comparable results, although this system revealed a slightly different sensitivity in showing the cytotoxicity of the drugs. By this assay, modest cross-resistance for ET-18-OCH3 and BM41.440 to Adriamycin was found only after 24 h incubation and decreased after 48 h incubation, with almost equal sensitivity to both drugs being shown by the parental (P388/W) and resistant lines (P388/ADR). Furthermore, findings from a human tumor-cloning assay were in accordance with these data, although they did not indicate cross-resistance for the P388/ADR cell line. These results suggest that certain ether lipids and derivatives might represent valuable anticancer drugs warranting further study in the setting of resistant disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225315     DOI: 10.1007/bf02994095

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  42 in total

Review 1.  Multidrug resistance.

Authors:  J A Moscow; K H Cowan
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

2.  Meeting highlights: William Guy Forbeck Foundation think tank on "multidrug resistance in cancer chemotherapy".

Authors:  B A Chabner; M M Gottesman
Journal:  J Natl Cancer Inst       Date:  1988-05-18       Impact factor: 13.506

3.  Alkyl-linked diglycerides inhibit protein kinase C activation by diacylglycerols.

Authors:  L W Daniel; G W Small; J D Schmitt; C J Marasco; K Ishaq; C Piantadosi
Journal:  Biochem Biophys Res Commun       Date:  1988-02-29       Impact factor: 3.575

Review 4.  Gene amplification in cultured animal cells.

Authors:  R T Schimke
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

5.  Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts.

Authors:  A Rosowsky; H Lazarus; G C Yuan; W R Beltz; L Mangini; H T Abelson; E J Modest; E Frei
Journal:  Biochem Pharmacol       Date:  1980-02-15       Impact factor: 5.858

6.  Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes.

Authors:  D A Haber; R T Schimke
Journal:  Cell       Date:  1981-11       Impact factor: 41.582

7.  Comparison of anthracycline concentrations in S180 cell lines of varying sensitivity.

Authors:  J M Siegfried; T R Tritton; A C Sartorelli
Journal:  Eur J Cancer Clin Oncol       Date:  1983-08

8.  Neoplastic cell inhibition with new ether lipid analogs.

Authors:  A Noseda; M E Berens; C Piantadosi; E J Modest
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

9.  Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog.

Authors:  S Akiyama; M M Cornwell; M Kuwano; I Pastan; M M Gottesman
Journal:  Mol Pharmacol       Date:  1988-02       Impact factor: 4.436

10.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  5 in total

1.  Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.

Authors:  G W Small; J C Strum; L W Daniel
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

Review 2.  Membrane-interactive lipids as experimental anticancer drugs.

Authors:  W E Berdel
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

3.  MDR1 causes resistance to the antitumour drug miltefosine.

Authors:  M Rybczynska; R Liu; P Lu; F J Sharom; E Steinfels; A D Pietro; M Spitaler; H Grunicke; J Hofmann
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

4.  Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).

Authors:  J Hofmann; I Utz; M Spitaler; S Hofer; M Rybczynska; W T Beck; D B Herrmann; H Grunicke
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Evaluation of in vitro and in vivo anti-inflammatory activity of biologically active phospholipids with anti-neoplastic potential in porcine model.

Authors:  Monika Vicenova; Katerina Nechvatalova; Katarina Chlebova; Zdenka Kucerova; Lenka Leva; Hana Stepanova; Martin Faldyna
Journal:  BMC Complement Altern Med       Date:  2014-09-19       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.